Tuesday, February 26, 2019

Shilpa Medicare gains 1% as Gemcitabine receives USFDA approvals

According to IQVIA MAT data released in December 2018, the US market for Gemcitabine (Injection) USP, 200mg/vial and 1g/vial was ~$11.7mn.

from India Infoline News Service https://ift.tt/2SYuvL8
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)